Deals Of The Week: GSK/Intercell, Novo Nordisk/ZymoGenetics, Lilly/Isis ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/. Also, check out the candidates for the Deals of the Year competition at the blog and cast your vote.
You may also be interested in...
Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines
Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Just days after Seattle Genetics lost Roche/Genentech as a partner for dacetuzumab (SGN-40), a CD40 antibody in development for lymphomas and multiple myeloma, the company has a new Big Pharma partner to head into the new year with. Seattle Genetics and Takeda's Millennium oncology unit announced a licensing deal Dec. 15 for brentuximab vedotin (SGN-35), an antibody-drug conjugate in development for lymphomas